What is Dario?
Dario operates at the intersection of consumer technology and chronic condition management, providing a digital ecosystem designed to foster lasting health behavior change. The platform distinguishes itself through a highly personalized, dynamic member experience that adapts to individual needs, moving beyond static health tracking to provide actionable, data-driven support. By addressing both well-being and complex chronic conditions, Dario delivers high-impact clinical outcomes that are increasingly attractive to enterprise clients seeking to optimize healthcare spend and improve member engagement. The company's decade-long experience in the direct-to-consumer space serves as the foundation for its current enterprise-level scaling strategy, allowing it to bridge the gap between individual health management and institutional health outcomes.
How much funding has Dario raised?
Dario has raised a total of $113.6M across 4 funding rounds:
Share Placement
$28.6M
Debt
$50M
Stock/Share Issuance
$17.5M
Private Equity
$17.5M
Share Placement (2020): $28.6M with participation from Nantahala Capital Management, LLC, Psagot investment house, Manchester Management Company LLC, Phoenix insurance, Mor provident fund, and Soleus Capital Management L.P.
Debt (2022): $50M led by OrbiMed
Stock/Share Issuance (2025): $17.5M, investors not publicly disclosed
Private Equity (2025): $17.5M, investors not publicly disclosed
Key Investors in Dario
OrbiMed
OrbiMed Advisors LLC is a specialized healthcare investment firm with deep expertise across biopharmaceuticals, medical devices, and digital health platforms, managing capital to support innovation from early-stage ventures to established organizations.
Nantahala Capital Management, LLC
An investment management firm that focuses on identifying high-growth opportunities within the public and private markets, often providing strategic capital to companies scaling their operations.
Soleus Capital Management L.P.
A specialized investment firm that focuses on the healthcare and life sciences sectors, providing strategic backing to companies that demonstrate significant potential for clinical and commercial impact.
What's next for Dario?
With the infusion of $17.5M, Dario is poised to enter a new phase of enterprise-level expansion. The strategic focus will likely center on deepening its integration capabilities within existing healthcare infrastructures and expanding its suite of connected health tools. As the company continues to refine its data-driven personalization engine, the emphasis will remain on demonstrating measurable clinical efficacy to institutional partners. This capital deployment will be critical in maintaining the company's competitive edge, enabling it to scale its operations while continuing to deliver the high-impact, personalized health experiences that have become its hallmark in the digital health market.
See full Dario company page
